Introduction to ASC37 Development
Ascletis Pharma Inc. has embarked on an exciting journey by selecting ASC37, a next-generation, once-monthly subcutaneously administered GLP-1R/GIPR/GCGR triple peptide agonist, for clinical development. This innovative therapy is designed to tackle obesity effectively and may revolutionize the way we approach metabolic diseases.
Significant Findings from Recent Studies
Recent head-to-head studies using non-human primates revealed promising results for ASC37. The average observed half-life of ASC37 was approximately 17 days, which is an impressive 7-fold longer than that of retatrutide. This remarkable half-life supports the feasibility of once-monthly subcutaneous dosing in humans, offering a significant advantage for patient compliance and treatment outcomes.
Moreover, ASC37 demonstrated a strong in vitro performance, being approximately 5 times more potent at GLP-1R, 4 times for GIPR, and another 4 times for GCGR compared to retatrutide. Such enhancements in activity highlight the therapy's potential effectiveness as a treatment for obesity and related conditions.
Clinical Development Timeline
Ascletis is proactively working towards the submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA). This application is expected to be submitted in the anticipated timeframe of the second quarter of 2026. The IND submission will pave the way for clinical trials that will bring ASC37 closer to market availability.
Innovative Technology Behind ASC37
The development of ASC37 employs Ascletis' cutting-edge Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies. These innovative tools have enabled scientists to discover and optimize ASC37, resulting in a medication capable of longer durations between doses. This design promotes scalability advantages during manufacturing, promising not only a more effective treatment but also a more efficient production process.
Potential Implications for the Market
As the challenge of obesity continues to grow globally, the need for effective medications is more pressing than ever. The superior in vitro potency and extended half-life of ASC37 exemplify its potential to become a game-changer in obesity treatments. With the support of advanced technologies, Ascletis positions itself to offer a clinically relevant alternative in the market.
Clinical Trials and Future Directions
Anticipated to begin in the second half of 2026, the Phase I clinical trials for ASC37 will allow researchers to further assess the efficacy and safety of this new treatment. Jinzi Jason Wu, Ph.D., Founder, Chairman, and CEO of Ascletis, expressed optimism by stating, "With ASC37, we are advancing a potentially more potent, next-generation triple agonist into the clinic which supports once-monthly dosing." This strategic move signifies Ascletis's commitment to enhancing therapeutic options for those struggling with obesity.
Combination Therapies with ASC37
While ASC37 is being developed as a standalone treatment option, there are also exciting plans to explore its viability in combination with other therapies. Ascletis aims to combine ASC37 with ASC36, a once-monthly subcutaneously administered amylin receptor peptide agonist. This combination approach may prove beneficial for patients dealing with multiple cardio-metabolic diseases, including diabetes and metabolic dysfunction-associated steatohepatitis (MASH).
Harnessing Advanced Technologies for Drug Development
Ascletis has streamlined its drug development process by leveraging the AISBDD and ULAP technologies, enabling the company to create others like ASC35 in addition to ASC36 and ASC37. Their proprietary ULAP technology allows precise control over the release rates of injected peptides, improving patient outcomes by reducing peak-to-trough ratios.
About Ascletis Pharma Inc.
Ascletis Pharma Inc. stands out as a fully integrated biotechnology company concentrating on developing and commercializing leading therapeutics aimed at treating metabolic diseases. The innovative application of its proprietary technologies, such as AISBDD and ULAP, showcases its alterative cures for both metabolic conditions and chronic weight management.
Frequently Asked Questions
What is ASC37?
ASC37 is a next-generation, once-monthly GLP-1R/GIPR/GCGR triple peptide agonist developed by Ascletis Pharma for treating obesity.
When is the expected IND submission?
The submission of the Investigational New Drug Application (IND) for ASC37 is anticipated in the second quarter of 2026.
What technologies are utilized in ASC37's development?
ASC37's development uses Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies.
How does ASC37 compare to retatrutide?
ASC37 has a significantly longer half-life and higher potency than retatrutide, making it a strong candidate for treating obesity.
What is the company's vision for ASC37?
Ascletis aims to advance ASC37 through clinical trials to eventually provide a potent therapeutic option for those suffering from obesity while exploring combination therapy benefits.
